Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer
Robert L. Ferris(University of Pittsburgh), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Dwight E. Heron(Bon Secours Mercy Health), Umamaheswar Duvvuri(City University of New York), Nicole C. Schmitt(Emory University), S. Kim, D.A. Clump(UPMC Hillman Cancer Center), James Ohr(University of Pittsburgh), Julie E. Bauman(George Washington University), J.L. Geiger(Cleveland Clinic), Jonas T. Johnson(University of Pittsburgh), Sumita Trivedi, William E. Gooding(UPMC Hillman Cancer Center)
Cited by 34
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688